Abstract: The invention relates to heteroaromatic carboxamides of formula (I), 1

Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) 1

Abstract: A novel method for the synthesis of piperazine and its derivatives of formula 1, 1

Abstract: This invention relates to novel multibinding compounds (agents) that are H1 histamine receptor antagonists and pharmaceutical compositions comprising such compounds. Accordingly, the multibinding compounds and pharmaceutical compositions of this invention are useful in the treatment and prevention of allergic diseases such as rhinitis, urticaria, asthma, and anaphylaxis, and the like.

Abstract: The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.

Abstract: Mixtures of chemical compounds are provided having antibacterial and other utility. The mixtures are formed, preferably in solution phase, from the reaction of a purine or pyrimiding heterocyclic scaffold with a set of related chemical substituients, optionally through employment of a tether moiety. Libraries formed in accordance with the invention have utility per se and are articles of commerce. They can be used to screen for pesticides, drugs and other biologically active compounds.

Abstract: Remedies/preventives (therapeutic or preventive agents) against frequent urination (pollakiuria)/urinary incontinence which contain as an active ingredient compound having a tropone structure or pharmacologically acceptable salt thereof and a novel compound having the tropone structure. The compounds having a tropone structure and having the above pharmacological effects are those represented by, for example, general (1): wherein R1 and R2 represent each a hydrogen atom, lower alkyl group, etc., R3 represents —OR or —NR2; R4, R5 and R12 represents each a hydrogen atom or a lower alkyl group, X represents a nitrogen atom or CH, Z represents —CHAr2, an unsubstituted or substituted phenyl, etc. m is 1 or 2. These compounds are novel ones excluding those wherein Z is —CHAr2.

Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed. The present invention is directed to compounds having the general formula I ##STR1## wherein: X is a halogen;Q is --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --, a single or a double bond, or --NR.sub.1 --;R.sub.1 is a C.sub.

Abstract: Novel non-dopaminergic antiischemic compounds have Formula I: ##STR1## wherein R=R.sub.1 and is independently H, C.sub.1-4 alky C.sub.1-4 alkoxy, C.sub.1-4 trihaloalkyl or halogen, or R and R.sub.1 may be taken together to form an --O(CH.sub.2).sub.m O-- (m=1 or 2);X=a 3-indolyl, phenyl, naphthalenyl or 2-benzothiazolyl residue;n=0, 1, 2 or 3; ##STR2## R.sub.2 =R.sub.3 and is independently H or C.sub.1-4 alkyl; and R.sub.4 =phenyl, 2-thienyl, 2-quinolinyl, 4-pyridinyl or substituted phenyl.

Abstract: The present invention provides novel compounds such as certain aryloxy indanamines which are useful as anti-depressants and as inhibitors of synaptic norepinephrine and serotonin uptake. The present invention also provides an improvement in the treatment of depression which comprises inhibiting synaptic serotonin and epinepherine uptake.

Abstract: Compositions comprising a pharmaceutically effective amount of a compound that impedes disruption of intact dense microspheres (DMS) by acting on DMS either to prevent disruption, or if disrupted, act on pre-disrupted DMS in such a way that, when the composition is administered to a test animal that has received an injection of DMS, it reduces the mean volume of tissue occupied by disrupted DMS, reduces the ratio of the number of inflammatory cells per DMS, or increases the ratio of the number of macrophages containing disrupted DMS per DMS, are useful for treating cerebral amyloidosis.

Abstract: Di-N-substituted piperazine or 1,4-di-substituted piperidine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein Q, n, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations with acetyl-cholinesterase inhibitors of compounds capable of enhancing acetylcholine release and having the above formula.

Abstract: Novel pharmaceutically/cosmetically-active biaromatic amido compounds have the structural formula (I): ##STR1## in which Ar is a radical selected from among those of the following formulae (a)-(e): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.

Abstract: Process for cross-coupling aromatic boron compounds with aromatic halogen compounds or perfluoroalkylsulfonates.In a process for preparing polycyclic aromatic compounds by cross-coupling aromatic boron compounds with aromatic halogen compounds or perfluoroalkylsulfonates under palladium catalysis in the presence of at least one water-soluble complex ligand, the reaction medium comprises an aqueous and an organic phase and the palladium is added in the form of a palladium compound soluble in the organic phase.Polycyclic aromatic compounds can thus be prepared economically and in very good yields and simultaneously very high purity, in particular without contamination by the complexing ligands.

Abstract: Tertiary aminoaryl compounds, such as N,N'dialkylaminoaryl compounds, are prepared using successive reductive steps without isolation therebetween, at high temperature and pressure. A nitroaryl compound is reduced using a ketone as both solvent and reactant in a reductive environment, and the resulting intermediate is further reacted with an aldehyde in the same reaction mixture without isolation to provide the second substituent on the amino group.

Abstract: Compositions comprising novel di-nitrogen heterocycle compounds containing at least one N-meta-substituted alkaryl group are prepared. The compounds of the present invention are useful as antibacterial and as other pharmaceutical agents and as intermediates for preparation of other pharmaceutical agents. In addition, compounds of the present invention are useful as research reagents.

Abstract: Trans isomers of 1-piperazino-1,2-dihydroindene compounds having formula (I), ##STR1## wherein X and Y are hydrogen, halogen, trifluoromethyl, alkyl, alkylthio, trifluoromethylthio, alkoxy, hydroxy, alkylsulfonyl, amino, alkylamino, nitro or cyano; Ar is a phenyl, thienyl or furyl group, each optionally substituted; R.sub.1 is hydrogen, or optionally hydroxy substituted alkyl, alkenyl, cycloalkyl or cycloalkylalkyl; R.sub.2 is alkyl, alkenyl, cycloalkyl, or cycloalkylalkyl; or R.sub.1 and R.sub.2 together form a 5 to 7-membered heterocyclic ring fused with the piperazine ring, which ring may be substituted with hydroxy; R.sub.3 is hydrogen, alkyl, alkenyl, cycloalkyl or cycloalkylalkyl; or R.sub.2 and R.sub.3 together form a 3 to 7-membered carbocyclic ring which is spiro-fused to the piperazine ring; and R.sub.4 is hydrogen or alkyl. The compounds of the invention have potent antagonist action on dopamine D.sub.

Abstract: Fused benzo compounds of formula I are provided, wherein A is a 2 to 6 membered hydrocarbon spacer group, B is a polar divalent group selected from a group (a); U is C, N or CH; X is a divalent 3-4 membered chain optionally comprising one or more heteroatoms; R.sup.1 is an aliphatic hydrocarbon group, arylalkyl or diphenylalkyl; R.sup.2 and R.sup.3 are hydrogen or alkyl or together form an ethylene or propylene bridge; R.sup.4, R.sup.5 and R.sup.6 are hydrogen or substituents; R.sup.7 and R.sup.8 are hydrogen or substituents including --COOR.sup.9 and --CONR.sup.10 R.sup.11 ; are 5-HT.sub.1A receptor ligands useful in the treatment of CNS disorders. Pharmaceutical compositions comprising the compounds and their use for the manufacture of a pharmaceutical preparation are also provided.

Abstract: A piperazine compound of the formula: ##STR1## wherein: X is carbonyl or sulfonyl;Y is a direct bond or lower alkylene; andR.sub.1, R.sub.2, R.sub.3, R.sub.4 are as defined herein. The compounds are advantageously used as Tachykinin antagonists in the treatment of respiratory diseases, ophthalmic diseases and inflammatory diseases, for example.

Abstract: A benzene, pyridine or pyrimidine derivative having the below shown formula is novel and useful as an anti-arteriosclerotic agent. ##STR1## wherein R.sup.1 stands for a lower alkyl group, an amino group which may be substituted, or the like; R.sup.2 stands for a group represented by the formula: ##STR2## (wherein R.sup.16 stands for an alkyl group having 1 to 6 carbon atoms, or the like) or the like; R.sup.3 stands for a group represented by the formula: --O--(CH.sub.2).sub.m --Y (Y stands for an imidazolyl or piperazinyl group, or the like and m is 1 to 6) or the like; R.sup.5 stands for a hydrogen atom, a lower alkyl group, or the like; A stands for a group represented by the formula: ##STR3## (wherein R.sup.6 stands for a hydrogen atom, a lower alkyl group, or the like), --N.dbd., or the like; and B stands for a group represented by the formula: ##STR4## (wherein R.sup.4 stands for a hydrogen or the like), --N.dbd., or the like.

Abstract: Piperidinyl-substituted cyclohexanes of Formula I have anti-ischemic properties: ##STR1## wherein R=R.sub.1 and is independently H or halogen; or R and R.sub.1 may be taken together to form an --O(CH.sub.2).sub.m O-- (m=1 or 2);X=a phenyl residue;R.sub.2 =R.sub.3 and is independently H or C.sub.1-4 alkyl; andR.sub.4 =phenyl or substituted phenyl wherein the phenyl group is mono-, or di-substituted with groups selected from: F, Cl, I and C.sub.1-4 alkoxy.

Abstract: The present invention relates to an oxindole compound having the formula 5-cyclohexyl-1,3-dihydro-1-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-2H-in dol-2-one for the prevention or treatment of cognitive dysfunctions.

Abstract: A process for preparing polycyclic aromatic compounds by cross-coupling aromatic boronic acids with aromatic halogen compounds or perfluoroalkylsulfonates in the presence of metallic palladium, if desired applied to a support material, as catalyst, wherein the coupling is carried out in the presence of a ligand and a base. The process of the invention allows the yield of polycyclic aromatic compounds to be significantly increased in comparison with processes not using a ligand and thus allows a yield optimum for the Pd(0)-catalyzed cross-coupling of aromatic boronic acids with aromatic halogen compounds to be achieved.

Abstract: Retinoid-like activity is exhibited by compounds of the formula ##STR1## where R is hydrogen or lower alkyl; A is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl or pyrazinyl; n is 0-5; and B is H, --COOH or an ester or amide thereof, --CH.sub.2 OH or an ether or ester derivative thereof, or --CHO or an acetal derivative thereof, or --COR.sub.1 or a ketal derivative thereof where R.sub.1 is --(CH.sub.2).sub.m CH.sub.3 where m is 0-4; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides novel substituted biphenyl pyrazines or pyrazine derivatives ("BPD") which are functional and have useful application as a monomer for a variety of high performance polymers such as polyester, polyarylate, polycarbonate, polyetherketones, epoxides, polyimides, polyamides, and polyamides-imides; and as pigments for coating compositions such as paints.

Abstract: An anilide compound represented by formula (I): ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different, each represent an alkyl group having 1 to 4 carbon atoms; n represents 0, 1 or 2; A represents an alkylene group having 1 to 14 carbon atoms or a group represented by --CH.sub.2 CO--; and Ar represents a phenyl group, a phenyl group substituted with a halogen atom, a nitro group, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, an alkanoyl group having 2 to 5 carbon atoms or a trifluoromethyl group, a benzyl group, a pyridyl group, a pyridyl group substituted with a halogen atom or a trifluoromethyl group, or a pyrimidyl group, or a salt thereof. The disclosed anilide compounds have potent ACAT inhibitory activity.

Abstract: Racemic or optically active new 3(2H)-pyridazinone derivatives, a process for the preparation thereof, pharmaceutical compositions comprising the same, to the use of the said 3(2H)-pyridazinone derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases.

Abstract: Diamine compounds of formula (I) or an addition salt thereof are provided: ##STR1## These compounds have an excellent cerebral protective action, are very safe, and exhibit a strong action when orally administered, and therefore, medicines containing such compounds are effective for treating disorders caused by cerebral hemorrhage, cerebral infarction, subarachnoid hemorrhage, transient ischemic attack, cerebrovascular disorders and the like, or preventing progress of such disorders.

Abstract: Biphenylyl tetrazoles for treating hypertension in mammals of the formula: ##STR1## where X is CH.sub.2, O, S, N--R.sup.4, NH, NCHO, NCOCH.sub.3 or NCO.sub.2 R.sup.4 ;R.sup.1 and R.sup.2 are the same or different and are C.sub.1-6 alkyl; andR.sup.4 is C.sub.1-6 alkyl;including methods and intermediates for the production of the same.

Abstract: Certain piperazinyl- and piperidinyl-substituted cyclohexanes have anti-ischemic properties.

Abstract: The invention relates to a piperazine derivative having the formula ##STR1## wherein each .phi. is a phenyl group which may independently be substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, CF.sub.3, and halogen, and Y is O or S, or a pharmaceutically acceptable salt thereof. The piperazine derivatives have sigma receptor affinity, and may be used for the treatment of psychosis.

Abstract: The compound (-)-N-t-butyl-4,4-diphenyl-2-cyclopentenylamine, or its hydrochloride salt has anticholinergic activity, and thus has a variety of pharmaceutical utilities.

Abstract: Compounds of structural formula: ##STR1## wherein Ar is an aromatic ring, B is a cyclic moiety fused to Ar of 5-7 members, X and Y are bridging groups, Q is a nitrogen containing heterocycle, R.sup.2 and R.sup.3 are H, substituted or unsubtituted C.sub.1-3 alkyl, C.sub.1-3 alkoxy, N(R).sub.2, halogen, CF.sub.3 or R.sup.5 and R.sup.1 is H or an aryl group.

Abstract: 7-(substituted)piperazinyl-1-ethyl-6-fluoro-4-oxo-3-quinolinecarboxylic acids, the pharmacologically acceptable salts thereof, compositions containing them, processes and intermediates for producing them, and methods of using them to treat bacterial infections in warm-blooded animals.

Abstract: A compound of the formula [II] or pharmaceutically acceptable salt thereof, ##STR1## wherein R.sup.1 is hydrogen or fluorine;R.sup.2 is hydrogen or fluorine;R.sup.3 is hydrogen, lower alkyl, lower alkoxy, halogen or lower alkylenedioxy;A is straight or branched lower alkylene having 1 to 6 carbon atoms; and n is 0 or 1,provided that at least one of R.sup.1 or R.sup.2 is fluorine. Such compound is useful for treatment of disorders of the cerebro-neural transmission system.

Abstract: Derivatives of 4-amino-1-trifluoromethyltetralines of general formula: ##STR1## wherein: X represents an aromatic nucleus, namely phenyl, naphthyl, or thienyl able to carry one to two substituents chosen from halogeno, hydroxy, C.sub.1 to C.sub.8 alkoxy or trifluoromethyl;R.sub.1 represents a hydrogen atom or a halogen, a hydroxy group, a C.sub.1 to C.sub.8 alkoxy group, in one of positions 5, 6 or 7, or even a methylenedioxy group in positions 5 and 6 or 6 and 7;R.sub.2 represents a hydrogen atom or a halogen, a hydroxy group, a C.sub.1 to C.sub.8 alkoxy group in one of the other positions 5, 6 or 7, andR.sub.3 and R.sub.4 each represent a hydrogen atom, a methyl group or a linear or branched C.sub.1 to C.sub.n alkyl group, n being 2 or more, possibly halogenated, hydroxylated or aminated, or R.sub.3 and R.sub.

Abstract: Certain ethanobicyclic amine compounds are described for treatment of CNS disorders such as psychotic disorders, convulsions, dystonia and cerebral ischemia. Compounds of particular interest are of the formula ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3, R.sup.4, Y and Z is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, phenalkyl, phenyl, alkoxy, phenoxy, phenalkoxy, alkoxyalkyl, halo, haloalkyl and hydroxyalkyl; wherein R.sup.3 and R.sup.4 may be taken together to form oxo;wherein each of R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, fluoroalkyl, cycloalkylalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein G within the nitrogen-containing cyclohetero moiety is selected from ##STR2## wherein R.sup.11 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, phenalkyl, alkoxyalkyl and hydroxyalkyl wherein each of R.sup.12 and R.sup.

Abstract: A method for treatment of disorders of the cerebro-neural transmission system which comprises administering a compound of the formula (I) or a pharmaceutically acceptable salt thereof in a therapeutically effective amount, either alone or in admixture with one or more pharmaceutically acceptable excipients, ##STR1## wherein Ar or Ar' is unsubstituted or substituted phenyl or pyridyl; R is hydrogen, lower alkyl, lower alkoxy, halogen or lower alkylenedioxy; A is C.sub.1 -C.sub.6 alkylene; and n is 0 or 1. A compound of the formula (II) or a pharmaceutically acceptable salt thereof, ##STR2## wherein R.sup.1 is hydrogen or fluorine; R.sup.2 is hydrogen or fluorine; R.sup.3 is hydrogen, lower alkyl, lower alkoxy, halogen or lower alkylenedioxy; A is lower C.sub.1 -C.sub.6 alkylene, and n is 0 or 1, provided that at least one of R.sup.1 or R.sup.2 is fluorine.

Abstract: The process is characterized in that the diethylamine salt or the ammonium salt of 2,5-dihydroxybenzenesulphonic acid is used as starting material, which salt is tosylated in an ammoniacal medium to lead in both cases to the production of the ammonium salt of 2,5-dihydroxybenzenesulphonic acid monotosylate, which in its turn is converted initially to the corresponding piperazine disalt which is separated in an aqueous medium, and finally in an aqueous-alcoholic medium the piperazine salt of 2,5-dihydroxybenzenesulphonic acid monotosylate, also known as piperazine sultosylate, is obtained.Medicinal applications.

Abstract: The compounds 2-trifluoromethyl-7-substituted-6,7,8,9-tetrahydro-[5H]-benzocycloheptenes are disclosed and disclosed to be useful in the treatment of metabolic illnesses such as diabetes, obesity, and their complications. A perferred compound is 2-trifluoromethyl-7-amino-6,7,8,9-tetrahydro-[5H-benzocycloheptane.

Abstract: 4-substituted cyclohexylamines of the formula ##STR1## where R is the group CR.sup.1 R.sup.2 R.sup.3, where R.sup.1, R.sup.2 and R.sup.3 are hydrogen, unsubstituted or substituted alkyl, alkoxy, alkylthio or cycloalkyl, with the proviso that at most one of the substituents R.sup.1, R.sup.2 and R.sup.3 is hydrogen, X is an alkylene group which, together with the N atom, forms a substituted or unsubstituted heterocyclic ring in which up to 2 carbon atoms may be replaced by O, N or S atoms, and salts thereof, and fungicides containing these compounds.

Abstract: This invention provides ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes which are selective inhibitors of serotonin reuptake.

Abstract: The invention relates to tetrahydronaphthalene and indane derivatives with the general formula I: ##STR1## wherein R.sup.1 represents zero to four substituents, which may be the same or different and are selected from OH, halogen, NO.sub.2, CN, CF.sub.3, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy and unsubstituted or C.sub.1 -C.sub.4 alkyl substituted amino;R.sup.2 represents C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkenyl and C.sub.1 -C.sub.4 alkynyl which may be substituted by halogen;R.sup.3 and R.sup.4 represent independently H, C.sub.1 -C.sub.4 alkyl or form together with the nitrogen atom a 5- or 6-membered ring;n has the value 0 or 1;ALK is an aliphatic hydrocarbon with 1-8 carbon atoms and their pharmaceutically acceptable salts.These new compounds are typical monoamine reuptake blockers with additional .alpha..sub.2 antagonist activity and show strong anti-depressant activity without being sedative.

Abstract: Cyclohexylamines of the formula ##STR1## where X is a single bond or an alkylene chain, Y is hydrogen or an aryl, cyclohexyl, 4-cyclohexylcyclohexyl, perhydro-1- or 2-naphthyl or piperidyl radical, R.sup.1 and R.sup.2 are hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, cycloalkyl, cycloalkenyl or arylalkyl, or R.sup.1 and R.sup.2 together form an alkylene group and, together with the N atom, form a ring, and acid addition salts thereof, with the exception of compounds in which X is a single bond, Y is cyclohexyl, R.sup.1 and R.sup.2 are hydrogen or methyl, and the compounds in which X is C.sub.6 -, C.sub.7 - and C.sub.8 -alkyl, Y is hydrogen and R.sup.1 and R.sup.2 together with the N atom whose substituents they are form a 2,6-dimethylmorpholine radical, and fungicides containing such cyclohexylamines.

Abstract: 7-(substituted)piperazinyl-1-ethyl-6-fluoro-4-oxo-3-quinolinecarboxylic acids, the pharmacologically acceptable salts thereof, compositions containing them, processes and intermediates for producing them, and methods of using them to treat bacterial infections in warm-blooded animals.

Abstract: Cyclic amine derivatives of the formula: ##STR1## or the pharmacologically acceptable salts thereof, wherein the symbols are as defined in the specification, as effective in relieving, curing or preventing mental symptoms due to cerebral vascular disorders.

Abstract: Novel 3-hydroxy-3-methylglutary-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.

Abstract: The present invention relates, by way of new industrial products, to phenylpiperazine derivatives selected from the group comprising 3-methyl-2-phenylpiperazine, 1-isopropyl-3-phenylpiperazine, 1-ethyl-2-methyl-3-phenylpiperazine, 1-isopropyl-2-methyl-3-phenylpiperazine, 1,2,4-trimethyl-3-phenylpiperazine, and (halogenophenyl)alkyl-piperazines of the formula: ##STR1## (wherein X.sub.o is F, Cl or Br, R.sub.1 is H or C.sub.1 -C.sub.4 alkyl, R.sub.2 is H or C.sub.1 -C.sub.2 alkyl and R.sub.3 is H or C.sub.1 -C.sub.4 alkyl, at least one of the symbols R.sub.1, R.sub.2 and R.sub.3 being different from H), and addition salts thereof.These new products are useful as antidepressants for the CNS.

Abstract: Disclosed are novel enamine quaternary compounds of the formula ##STR1## wherein m=1, 2 or 3 and n=1, 2 or 3 with the proviso that m+n=3, 4 or 5; R.sup.1 and R.sup.2 are independently lower alkyl or hydrogen, and R.sup.3 and R.sup.4 are independently selected from the group consisting of lower alkyl, lower cycloalkyl lower alkyl, lower alkenyl, phenyl lower alkyl, thienyl lower alkyl, furyl lower alkyl, lower alkoxy lower alkyl, halogenated lower alkyl, lower alkyloyloxo or lower alkyloyloxy lower alkyl or wherein NR.sup.3 R.sup.4 together comprise a heterocycle ring; and wherein X.sup.- represents a pharmaceutically acceptable anion. Pharmaceutical compositions containing the same when administered to warm-blooded animals exhibit a muscle relaxant effect characterized by excellent onset and recovery times. Also disclosed are methods of making the enamine quaternary compounds.

Abstract: Quaternary ammonium retinoate, characterized in that it corresponds to the formula: ##STR1## in which: X-- denotes either an all-trans-retinoate of formula (I): ##STR2## or a 13-cis= retinoate of formula: ##STR3## (i) R.sub.1, R.sub.2 and R.sub.3, which may be identical or different, denote a saturated C.sub.1 -C.sub.4 linear alkyl group capable of bearing one or more hydroxyl group(s) at the end of the chain or in the chain;R.sub.4 denotes a C.sub.12 -C.sub.18 linear alkenyl or alkyl group;(ii) R.sub.3 denotes a group: ##STR4## in which n equals 0 or 1, R.sub.5 denotes a hydrogen atom, a hydroxyl, a halogen atom, a C.sub.1 -C.sub.18 -hydroxyl alkyl or alkyl group or a C.sub.2 to C.sub.18 acyl group;R.sub.1, R.sub.2 and R.sub.4 having the same meanings as those under (i);(iii) R.sub.1 and R.sub.2 can form an aliphatic heterocycle optionally containing an oxygen atom, another nitrogen atom or a sulphur atom;R.sub.3 and R.sub.4 having the same meanings as those under (i) and (ii).